EVALUATION OF SWITCHING BETWEEN BRANDED AND GENERIC LATANOPROST AFTER PATENT EXPIRATION IN THE NETHERLANDS

被引：0
|
作者：
Houweling, Leanne [1 ]
Woodruff, Seth [2 ]
Houben, Eline [1 ]
Liu, Larry [2 ,3 ]
Herings, Ron [1 ]
Subramaniam, Kannan [4 ]
机构：
[1] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands
[2] Pfizer Inc, New York, NY USA
[3] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[4] Pfizer Australia, Sydney, NSW, Australia
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2014年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
63
引用
收藏
页码：100 / 100
页数：1
相关论文
共 17 条
  • [1] Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
    Dewang Angmo
    Meenakshi Wadhwani
    Thirumurthy Velpandian
    Ankita Kotnala
    Ramanjit Sihota
    Tanuj Dada
    [J]. International Ophthalmology, 2017, 37 : 423 - 428
  • [2] Compliance after switching from branded to generic statins
    Romanelli, Robert J.
    Jukes, Trevor
    Segal, Jodi B.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (10) : 1093 - 1100
  • [3] Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
    Angmo, Dewang
    Wadhwani, Meenakshi
    Velpandian, Thirumurthy
    Kotnal, Ankita
    Sihota, Ramanjit
    Dada, Tanuj
    [J]. INTERNATIONAL OPHTHALMOLOGY, 2017, 37 (02) : 423 - 428
  • [4] Time to Marketing of Generic Drugs After Patent Expiration in Canada
    Lexchin, Joel
    [J]. JAMA NETWORK OPEN, 2021, 4 (03)
  • [5] Correction to: Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations
    Dewang Angmo
    Meenakshi Wadhwani
    Thirumurthy Velpandian
    Ankita Kotnala
    Ramanjit Sihota
    Tanuj Dada
    [J]. International Ophthalmology, 2022, 42 : 363 - 363
  • [6] ESTIMATES OF THE PRICE ELASTICITY OF SWITCHING BETWEEN BRANDED AND GENERIC DRUGS
    Terrizzi, Sabrina
    Meyerhoefer, Chad
    [J]. CONTEMPORARY ECONOMIC POLICY, 2020, 38 (01) : 94 - 108
  • [7] Differences in rates of switchbacks after switching from - branded to authorized generic and branded to generic drug products: cohort study
    Desai, Rishi J.
    Sarpatwari, Ameet
    Dejene, Sara
    Khan, Nazleen F.
    Lii, Joyce
    Rogers, James R.
    Dutcher, Sarah K.
    Raofi, Saeid
    Bohn, Justin
    Connolly, John
    Fischer, Michael A.
    Kesselheim, Aaron S.
    Gagne, Joshua J.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 361
  • [8] Switching from branded to generic risperidone in patients with schizophrenia: An estimation of potential economic consequences in the Netherlands
    Van Nooten, F.
    Rijnders, C.
    Brown, R.
    Van Agthoven, M.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A296 - A296
  • [9] SEIZURE COUNT WHILE SWITCHING BACK AND FORTH BETWEEN BRANDED AND GENERIC OXCARBAZEPINE
    Hagemann, G.
    Fuchs, M.
    Zinke, J.
    Witte, O.
    [J]. EPILEPSIA, 2009, 50 : 111 - 111
  • [10] A Case of Akathisia After Switching From Branded to Generic High-Dose Olanzapine
    Goldberg, Joseph F.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 497 - 497
12